Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi has launched a Phase 3 clinical study titled A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn’s Disease. The study aims to assess the efficacy and safety of the drug duvakitug, offering potential advancements in treatment for Crohn’s Disease, a condition affecting millions globally.
The study tests the drug duvakitug, administered via subcutaneous injection, against a placebo. The goal is to determine its effectiveness in maintaining remission in patients with moderate to severe Crohn’s Disease.
This interventional study employs a randomized, parallel assignment model with quadruple masking, ensuring unbiased results. Its primary purpose is treatment-focused, aiming to provide a new therapeutic option for Crohn’s Disease patients.
The study began on September 15, 2025, with a primary completion date set for the pivotal maintenance sub-study at 40 weeks, and an estimated overall completion after 286 weeks. The latest update was submitted on October 1, 2025, indicating active recruitment.
The outcome of this study could significantly impact Sanofi’s market position, potentially boosting its stock performance and investor confidence if results are favorable. Competitors in the Crohn’s Disease treatment market will be closely monitoring these developments.
This study is ongoing, with further details available on the ClinicalTrials portal.